Sriram Krishnaswami
Queensland University of Technology(AU)Pfizer (United States)(US)Certara (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Systemic Lupus Erythematosus Research, Chronic Lymphocytic Leukemia Research, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis(2012)931 cited
- → Tofacitinib versus Methotrexate in Rheumatoid Arthritis(2014)765 cited
- → Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial(2013)715 cited
- → Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study(2013)577 cited
- → The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo(2009)542 cited
- → Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial